Attention Deficit Hyperactivity Disorder Industry Growth Expected to Reach $22.59 Billion by 2029 at a CAGR of 6.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Attention Deficit Hyperactivity Disorder Market Growth in 2025?
The market for attention deficit hyperactivity disorder has seen robust growth in the past few years. It is projected to expand from $16.29 billion in 2024 to $17.43 billion in 2025, at a compound annual growth rate of 7.0%. Factors such as an increasing number of ADHD cases, a rise in ADHD diagnoses among children, growing ADHD awareness, higher healthcare spending, and governmental mental health initiatives contribute to the growth experienced during the historic period.
What Is the Forecast for the Attention Deficit Hyperactivity Disorder Market Size Through 2029?
In the coming years, robust growth is projected for the market of attention deficit hyperactivity disorder. The market is predicted to expand to $22.59 billion by 2029, with a compound annual growth rate of 6.7%. The causes for this anticipated growth during the forecast period include larger numbers of children and adults seeking treatment, improved medical infrastructure, increasing adoption of personalized medication, wider recognition of mental health problems, and a rising trend in the use of additives and preservatives in kids’ diets. The forecast period is also expected to see major trends such as technological enhancements and innovative therapies, improvements in diagnosis and treatment procedures, the launch of new therapeutic medications, a shift away from stimulant drugs, and advancement in pharmaceutical treatments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21108&type=smp
What are the Key Market Players in Attention Deficit Hyperactivity Disorder Market and How They’re Evolving?
Major companies operating in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P.
What Are the Primary Growth Drivers in the Attention Deficit Hyperactivity Disorder Market?
The increase in personalized medicine usage is anticipated to boost the attention deficit hyperactivity disorder (ADHD) market’s growth in the future. Personalized medicine refers to a medical strategy that customizes treatments based on a person’s genetic, environmental, and lifestyle elements, making healthcare more precise and potent. The employment of personalized medicine is linked with genomic technology advancements, which allow treatment customizations to a person’s genetic blueprint, resulting in more efficient and targeted therapy. The role of ADHD in personalized medicine is significant, providing personalized treatment plans that account for an individual’s specific genetic, environmental, and behavioral aspects, leading to more productive and targeted responses. For instance, a report published by the Personalized Medicine Coalition (PMC), a non-profit organization based in the US, stated in February 2024 that personalized medicines made up over one-third of new FDA drug approvals for the fourth year in a row in 2023. The FDA approved 16 new treatments for rare diseases, an increase from 6 in 2022, along with 7 cancer drugs and 3 for other conditions. As a result, the rising adoption of personalized medicine is fueling the growth of the attention deficit hyperactivity disorder market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21108&type=smp
What Are the Leading Segments in the Global Attention Deficit Hyperactivity Disorder Industry?
The attention deficit hyperactivity disorder market covered in this report is segmented –
1) By Type: Stimulants, Non-Stimulants
2) By Age Group: Children, Adults
3) By Gender: Male, Female
4) By Dosage Form: Tablets, Capsules, Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications, Amphetamine-based Medications, Mixed Amphetamine Salts, Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay), Bupropion (Wellbutrin)
What Are the Key Market Trends in the Attention Deficit Hyperactivity Disorder Industry?
Leading corporations in the attention deficit hyperactivity disorder (ADHD) sector are concentrating their efforts on the creation of pioneering medications, including extended-release tablets. These innovations aim to elevate therapeutic performance, amplify patient adherence, and deliver enduring symptom management. Extended-release tablets have been engineered to slowly distribute the medication over a period, offering stable symptom management all day with just a single dosage. This reduces the requirement for multiple dosages, enhancing the simplicity and commitment to the treatment regimen for those with ADHD. For instance, in February 2022, JAMP Pharma Group (based in Canada) launched Guanfacine XR, a generic version of Takeda Canada Inc.’s INTUNIV XR, a trademark medication developed to treat ADHD. This medication is a lengthy-acting form of guanfacine, designed to influence specific brain receptors to enhance attention, impulse control, and reduce hyperactivity. The medication is offered in several dosages (1 mg, 2 mg, 3 mg, and 4 mg) and is packed in a 100-count bottle, which allows for adaptable therapy options.
Access The Full Report Here:
What Is the Regional Outlook for the Attention Deficit Hyperactivity Disorder Market?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21108
This Report Delivers Insight On:
1. How big is the attention deficit hyperactivity disorder market, and how is it changing globally?
2. Who are the major companies in the attention deficit hyperactivity disorder market, and how are they performing?
3. What are the key opportunities and risks in the attention deficit hyperactivity disorder market right now?
4. Which products or customer segments are growing the most in the attention deficit hyperactivity disorder market?
5. What factors are helping or slowing down the growth of the attention deficit hyperactivity disorder market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
